Veradigm’s Investment in Artificial Intelligence Highlighted in Forbes Magazine Article

This week, Forbes published a new article that highlights Veradigm's recent acquisition of ScienceIO and what the addition of this dynamic new element to the Veradigm Network can mean for the future of the company, and healthcare overall.

"We moved quickly because we knew that there was going to come a day when we would have generative AI all around us," Yin Ho, Veradigm's interim Chief Executive Officer, told Forbes.

As Forbes points out, "ScienceIO's models can reduce the labor-intensive process of cleaning and structuring hastily written, abbreviation-filled doctor's notes from months to days. Unlike other datasets that come from large academic medical centers in major cities, Veradigm's data includes substantial swaths of the rural U.S."

Forbes also focused on the unique combination of the AI capabilities brought by ScienceIO along with the Veradigm Network collection of data. As the article states, "ScienceIO's models paired with Veradigm's largely untapped asset - medical record data rights - could prove to be a potent combination."

This ability will help Veradigm to align patient data across healthcare provider practices, including linking to claims data. This more comprehensive view of patient data can help biopharma companies better understand how patients react to different therapies over time, in real-world conditions. As Forbes highlights, "Recently the FDA has started allowing real-world data from patients outside clinical trials to speed up the drug approval process, which also has the potential to significantly reduce costs. The market for this type of data is expected to hit $7.5 billion this year, according to investment advisory firm Beecher and Co. and is growing at a rate of over 20%."

Click here to read the Forbes article.